Search

Your search keyword '"Carboxypeptidase B2 blood"' showing total 286 results

Search Constraints

Start Over You searched for: Descriptor "Carboxypeptidase B2 blood" Remove constraint Descriptor: "Carboxypeptidase B2 blood"
286 results on '"Carboxypeptidase B2 blood"'

Search Results

1. Fibrinolysis is impaired in patients with primary immune thrombocytopenia.

2. Reduced protein carbonylation on hormone therapy is associated with improved fibrinolysis in postmenopausal women: the impact of PAI-1 and TAFI activity.

3. Identification and validation of coagulation and fibrinolytic-related diagnostic biomarkers for ulcerative colitis by bioinformatics analysis.

4. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.

5. Increased Thrombin-Activatable Fibrinolysis Inhibitor in Response to Sublingual Immunotherapy for Allergic Rhinitis.

6. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology.

7. Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6 months after obesity surgery.

8. Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial.

9. Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.

10. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission

11. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.

12. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.

13. Serum Proteomic Changes as Candidate Biomarkers of Intermediate Liver Fibrosis in Chronic Hepatitis B Infection.

14. Plasma Protein Oxidation as a Determinant of Impaired Fibrinolysis in Type 2 Diabetes.

15. Presence of thrombophilia and levels of coagulation factors, coagulation inhibitors and TAFI do not affect global haemostasis or bleeding phenotype in patients with haemophilia A.

16. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.

17. Thrombin activatable fibrinolysis inhibitor as an indicator of the severity of acute pancreatitis.

18. Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice.

19. Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats.

20. A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.

21. Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty.

22. Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.

23. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.

24. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).

25. Dose-Response Relationship Between Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) and Stroke: A Chinese Case-Control Study.

26. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.

27. Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia.

28. Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.

29. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.

30. Fibrinolysis parameters in Sudanese women with severe preeclampsia.

31. Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke.

32. Impacts of laparoscopic hysterectomy on functions of coagulation and fibrinolysis system.

33. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.

34. A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection.

35. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.

36. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.

37. Levels of thrombin-activatable fibrinolysis inhibitor and platelet-activating factor in recurrent pregnancy loss patients.

38. Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.

39. Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.

40. Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis.

41. Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.

42. Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.

43. The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile.

44. Inhibition of Thrombin-Activated Fibrinolysis Inhibitor Increases Survival in Experimental Kidney Fibrosis.

45. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.

46. Exercise stress testing enhances blood coagulation and impairs fibrinolysis in asymptomatic aortic valve stenosis.

47. Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases.

48. Thrombin activatable fibrinolysis inhibitor : its role in slow coronary flow.

49. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.

50. Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.

Catalog

Books, media, physical & digital resources